Parathyroid adenoma secondary prevention
Jump to navigation
Jump to search
|
Parathyroid adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parathyroid adenoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Parathyroid adenoma secondary prevention |
|
Risk calculators and risk factors for Parathyroid adenoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Secondary prevention of parathyroid adenoma causing primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo parathyroidectomy. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism due to parathyroid adenoma, not undergoing parathyroidectomy.
Secondary Prevention
- Secondary prevention of primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo parathyroidectomy. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing parathyroidectomy. These guidelines include:[1]
- Serum calcium
- Serum calcium should be monitored annually.
- Skeletal monitoring
- Dual-energy X-ray absorptiometry (DEXA) is used for skeletal monitoring. DEXA should be done every 1-2 years (at 3 sites).
- X-ray or vertebral fracture assessment of spine may be done if indications are present such as height loss, and/or back pain.
- Renal monitoring
- Estimated glomerular filtration rate (eGFR) and serum creatinine should be done annually.
- 24-hour biochemical stone profile, renal imaging by x-ray, ultrasound, or CT scan may be considered if renal stones are suspected.
- Serum calcium
References
- ↑ Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C; et al. (2014). "Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop". J Clin Endocrinol Metab. 99 (10): 3561–9. doi:10.1210/jc.2014-1413. PMC 5393490. PMID 25162665.